Causes and consequences of critical bleeding and mechanisms of blood coagulation

Pharmacotherapy

Volumn 27, Issue 9 II SUPPL., 2007, Pages

  Zimmerman, Lisa Hall ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

Blood coagulation; Critical bleeding; Pharmacy practice

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA TOCOPHEROL; ALTEPLASE; ANCROD; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARDEPARIN; ARGATROBAN; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CERTOPARIN; CHLORAL HYDRATE; CHLORDIAZEPOXIDE; CIMETIDINE; CIPROFLOXACIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DROTRECOGIN; FIBRINOLYTIC AGENT; GINKGO BILOBA EXTRACT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; TICLOPIDINE; UNINDEXED DRUG; WARFARIN;

BLEEDING; BLOOD CLOTTING; BLOOD VOLUME; DRUG MECHANISM; DRUG POTENTIATION; HEMOSTASIS; HUMAN; PHARMACIST; REVIEW;

EID: 34548301665     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9part2.45s     Document Type: Review

References (86)

1. Greenburg AG. Indications for transfusion. In: Wilmore DW, Cheung LY, Harken AH, Holcroft JW, Meakins JL, eds. Scientific American surgery. New York: Scientific American, Inc., 1989:1-19.
2. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94:537-43.
3. Bush MT, Roy N. Hemophilia emergencies. J Emerg Nurs 1995;21:531-8.
4. Franchini M. Acquired hemophilia A. Hematology 2006;11:119-25.
5. Santoso JT, Saunders BA, Grosshart K. Massive blood loss and transfusion in obstetrics and gynecology. Obstet Gynecol Surv 2005;60:827-37.
6. Vaslef SN, Knudsen NW, Neligan PJ, Sebastian MW. Massive transfusion exceeding 50 units of blood products in trauma patients. J Trauma 2002;53:291-5.
7. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003;24:607-22.
8. Hoffman MM, Monroe DM. Rethinking the coagulation cascade. Curr Hematol Rep 2005;4:391-6.
9. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003;10:797-811.
10. Vamvakas EC. Epidemiology of red blood cell utilization. Transfus Med Rev 1996;10:44-61.
11. Baskett TF. Resuscitation greats: Ambroise Paré and the arrest of haemorrhage. Resuscitation 2004;62:133-5.
12. Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006;13:462-70.
13. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth 2004;93:842-58.
14. Richman JM, Rowlingson AJ, Maine DN, Courpas GE, Weller JF, Wu CL. Does neuraxial anesthesia reduce intraoperative blood loss? A meta-analysis. J Clin Anesth 2006;18:427-35.
15. Rutherford EJ, Skeete D, Schooler WG, Fakhry SM. Hematologic principles in surgery. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston textbook of surgery: the biological basis of modern surgical practice, 17th ed. Philadelphia: Elsevier Saunders, 2004:113-36.
16. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. Am J Med Qual 1994;9:172-83.
17. Block JE. Severe blood loss during spinal reconstructive procedures: the potential usefulness of topical hemostatic agents. Med Hypotheses 2005;65:617-21.
18. Callaghan JJ, O'Rourke MR, Liu SS. Blood management: issues and options. J Arthroplasty 2005;20:51-4.
19. Moul JW, Sun L, Wu H, et al. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol Oncol 2003;21:447-55.
20. Han M, Alfert HJ, Partin AW. Retropubic and suprapubic open prostatectomy. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Campbell's urology, 8th ed. Philadelphia: Saunders, 2002:1423-34.
21. Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006;43:559-63.
22. Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001;72:S1821-31.
23. Hartmann M, Sucker C, Boehm O, Koch A, Loer S, Zacharowski K. Effects of cardiac surgery on hemostasis. Transfus Med Rev 2006;20:230-41.
24. Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sang 2005;89:123-7.
25. Meng ZH, Wolberg AS, Monroe DM III, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886-91.
26. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
27. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726-48.
28. DeLoughery TG. Critical care clotting catastrophies. Crit Care Clin 2005;21:531-62.
29. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
30. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:S204-33.
31. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 2006;60:S3-11.
32. Wittkowsky AK. Thrombosis. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, eds. Applied therapeutics: the clinical use of drugs. Philadelphia: Lippincott Williams & Wilkins, 2001:14-1-14-33.
33. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004;100:722-30.
34. Litle VR, Swanson SJ. Postoperative bleeding: coagulopathy, bleeding, hemothorax. Thorac Surg Clin 2006;16:203-7.
35. Wallen NH, Ladjevardi M. Influence of low- and high-dose aspirin treatment on thrombin generation in whole blood. Thromb Res 1998;92:189-94.
36. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59:438-42.
37. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:S234-64.
38. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Plavix® (clopidogrel bisulfate tablets) package insert. Bridgewater, NJ; 2007.
39. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:5258-75.
40. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 2004;126:S188-203.
41. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007;21:37-48.
42. Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 2005;128:958-69.
43. GlaxoSmithKline. Arixtra® (fondaparinux sodium) injection package insert. Research Triangle Park, NC; 2005.
44. White CM. Thrombin-directed inhibitors: pharmacology and clinical use. Am Heart J 2005;149:S54-60.
45. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004;43:963-81.
46. Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 2005;60:565-74.
47. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study - a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000;283:2395-403.
48. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 2006;368:1871-8.
49. Ellis K, Boccalandro F, Burjonroppa S, et al. Risk of bleeding complications is not increased in patients undergoing rescue versus primary percutaneous coronary intervention for acute myocardial infarction. J Intervent Cardiol 2005;18:361-5.
50. Mosnier LO, Griffin JH. Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci 2006;11:2381-99.
51. Eli Lilly. Xigris® (drotrecogin alfa [activated]) package insert. Indianapolis, IN; 2006.
52. Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective. Am Heart J 1999;138:307-16.
53. Hodges PJ, Kam PC. The peri-operative implications of herbal medicines. Anaesthesia 2002;57:889-99.
54. Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol 2006;107:927-41.
55. Magann EF, Lanneau GS. Third stage of labor. Obstet Gynecol Clin North Am 2005;32:323-32.
56. Hulka F, Mullins RJ, Frank EH. Blunt brain injury activates the coagulation process. Arch Surg 1996;131:923-7.
57. Hardy JF, De Moerloose P, Samama M. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2004;51:293-310.
58. Ebb DH, Bray GL. Bleeding disorders of childhood. In: Grenvik A, Ayres SM, Holbrook PR, Shoemaker WC, eds. Critical care, 4th ed. Philadelphia: WB. Saunders Company, 2000:1728-43.
59. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995;127:355-63.
60. Celikel S, Buyukasik Y, Karakaya G, Kalyoncu AF. Hereditary angioedema associated with heterozygous factor V Leiden mutation in a patient with purpura fulminans. Int Arch Allergy Immunol 2007;142:175-8.
61. Betrosian AP, Berlet T, Agarwal B. Purpura fulminans in sepsis. Am J Med Sci 2006;332:339-45.
62. Shander A, Goodnough LT. Update on transfusion medicine. Pharmacotherapy 2007;27(9 pt 2):S57-68.
63. Papp Z. Massive obstetric hemorrhage. J Perinat Med 2003;31:408-14.
64. Solomon JA, Abrams L, Lichtenstein GR. GI manifestations of Ehlers-Danlos syndrome. Am J Gastroenterol 1996;91:2282-8.
65. Nagy SW, Marshall JB. Aortoenteric fistulas: recognizing a potentially catastrophic cause of gastrointestinal bleeding. Postgrad Med 1993;93:211-22.
66. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma Stress 2007;62:112-19.
67. Dutton RP, Carson JL. Indications for early red blood cell transfusion. J Trauma 2006;60:S35-40.
68. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007;62:307-10.
69. Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 1997;42:857-61.
70. Hameed SM, Aird WC, Cohn SM. Oxygen delivery. Crit Care Med 2003;31:S658-67.
71. Tisherman SA, Barie P, Bokhari F, et al. Clinical practice guideline: endpoints of resuscitation. J Trauma 2004;57:898-912.
72. Eastridge BJ, Malone D, Holcomb JB. Early predictors of transfusion and mortality after injury: a review of the databased literature. J Trauma 2006;60:S20-5.
73. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003;289:959-62.
74. Goodnough LT. Risks of blood transfusion. Crit Care Med 2003;31:S678-86.
75. Kuriyan M, Carson JL. Blood transfusion risks in the intensive care unit. Crit Care Clin 2004;20:237-53.
76. Sandler SG, Yu H, Rassai N. Risks of blood transfusion and their prevention. Clin Adv Hematol Oncol 2003;1:307-13.
77. Maughan KL, Heim SW, Galazka SS. Preventing postpartum hemorrhage: managing the third stage of labor. Am Fam Physician 2006;73:1025-8.
78. Campbell JE. BTLS: basic trauma life support: for paramedics and other advanced providers, 5th ed. Upper Saddle River, NJ: Pearson Education, Inc, 2004.
79. Dutton RP, Lefering R, Lynn M. Database predictors of transfusion and mortality. J Trauma 2006;60:S70-7.
80. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006;117:569-77.
81. Aird WC. Coagulopathy. In: Fink MP, Abraham E, Vincent JL, Kochanek PM, eds. Critical care, 5th ed. Philadelphia: Elsevier Saunders, 2005:95-7.
82. Wojciechowski PJ, Samol N, Walker J. Coagulopathy in massive transfusion. Int Anesthesiol Clin 2005;43:1-20.
83. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
84. Macfarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 1964;202:498-9.
85. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-12.
86. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9.